Settlement Agreement Between Plaintiff States and UBS (Dec. 21, 2018)

Forty plaintiff states reached a $68 million settlement with UBS for fraudulent conduct involving interest rate manipulation that had a significant impact on consumers and financial markets around the world. UBS’ fraudulent conduct involved the manipulation of LIBOR (the London Interbank Offered Rate). LIBOR is a benchmark interest rate that affects financial instruments worth trillions…

Read More →

Attorney General v. Florida Cancer Specialists and Research Institute, LLC (Fl. Cir. Ct., Leon Cty., Apr. 30, 2020)

Florida reached a multimillion-dollar agreement with one of the largest oncology medical practices in Florida to resolve state antitrust and consumer protection concerns. The proposed consent decree with Florida Cancer Specialists & Research Institute, LLC follows a civil antitrust investigation into whether the health care provider entered into illegal agreements with competitors that allocated geographic…

Read More →

NAAG Supports Daniel’s Law

The Daniel Anderl Judicial Security and Privacy Act honors the memory of the son of Judge Esther Salas of the U.S. District Court for the District of New Jersey. Daniel was tragically killed on July 19, 2020, when an armed assailant—a deranged attorney who had appeared in a case before Judge Salas—appeared at her home and opened fire. Daniel was only 20. Judge Salas’s husband was also shot in the attack. 

Read More →

NAAG Urges Congress to Extend CARES Act Spending Deadline

With COVID-19 cases rising daily in much of the country and many states still under a health emergency declaration, we urge Congress to amend the CRF program to allow state and local governments to spend the funding at least until December 31, 2021.

Read More →

NAAG Endorses Edith’s Bill

Throughout the country, attorneys general are fighting senior fraud and abuse. In 2019, several state attorneys general partnered with the U.S. Department of Justice and other federal partners to conduct the largest-ever nationwide elder fraud sweep against perpetrators who had repeatedly targeted seniors, resulting in losses of over $750 million.

Read More →

Attorneys General Urge Congress to Adopt Key Changes to the Victims of Crime Act (VOCA)

As state Attorneys General, we are often the administrators of grant funding, through our state compensation programs or otherwise, financed directly from the Fund. In order to ensure the predictability and sustainability of these critical funds, change must be enacted to support our states’ ability to effectively serve victims and survivors of crime for years to come.

Read More →

NAAG Endorses Stopping Overdoses of Fentanyl Analogues (SOFA) Act

States and localities are on the front line of this crisis and are a large part of winning the battle from both a law enforcement and public health perspective.

Read More →

Florida v. Abbott Laboratories and Geneva Pharmaceuticals, Inc.

The brand name maker of the prescription drug Hytrin, Abbott, entered into an agreement with Geneva to keep Geneva’s generic version of Hytrin off the market. Geneva was paid a substantial amount of money by Abbott while Abbott continued to collect monopoly profits on its name brand drug. Because of federal regulatory system for new generic entry, Geneva effectively blocked the entry of other generic drug makers. The matter settled in conjunction with MDL litigation.

Read More →

California et al. v. Teikoku Seikayu Co.(Lidoderm), No. 3:18-cv-00675 (N.D. Cal. 01/31/18)

Plaintiff states alleged that defendant, the producer of Lidoderm (pain medication), paid or incentivized generic drug makers to delay entry into market to protect its monopoly on Lidoderm. (“pay for delay”) The settlement agreement, which expires in twenty years, prohibits Teikoku from entering into agreements that restrict generic drug manufacturers from researching, manufacturing, marketing, or selling products for a period of time and requires Teikoku to cooperate in an ongoing investigation into similarly anticompetitive conduct by other drug manufacturers, among other things.

Read More →

Florida v. General Chemical Corp. No. 2:17-00384 (D.N.J. Jan. 19, 2017)

Plaintiff state filed action in federal court alleging market allocation and price-fixing among manufacturers of the chemical liquid aluminum sulfate, which is a coagulant used to remove impurities and other substances from water. It is used primarily by municipalities in wastewater treatment. There are high barriers to entry and substitution is difficult. There have been several USDOJ indictments in the industry. The complaint alleged that the defendants conspired to circumvent competitive bidding and independent pricing and to raise liquid aluminum sulfate prices by submitting artificially inflated bids in Florida from 1997 through at least February 2012. The state alleged that fraudulent concealment of the conspiracy tolled the statute of limitations.

Read More →